The Latest On Premier Science In Medical Oncology At The 33rd ESMO Congress, Stockholm, Sweden, Sept. 12-16, 2008
Main Category: Cancer / OncologyAlso Included In: Conferences; Radiology / Nuclear Medicine; Medical Devices / Diagnostics
Article Date: 01 Aug 2008 - 0:00 PDT
Congress Highlights
Some of the highlights that will be presented during the educational and scientific program at Europe's premier medical oncology meeting include:
- Molecular analysis for target discovery: Identification of 'Achilles' heel'
MicroRNa, SiRNA libraries
Protein array - Innovation in breast cancer
Modulation of resistance to anti-Her2 therapies
Evaluation of predictive markers on circulating tumor cells
New targets for triple negative tumors
Stem cell as a potential target
Tools in daily clinical practice to improve treatment - Tailoring therapy in lung cancer
Medical implications of resistance to EGFR
Personalized cancer therapies for non-EGFR receptor-dependent tumors - New pathways in targeted therapy
IGF-1, PI 3, PARP, Met - Optimal integration of newer agents in the treatment of advanced CRC
Genomic and pharmacogenetic markers for treatment decision
Upfront sequential vs. combination chemotherapy - Renal cell cancer
VEGF biology and resistance
mTOR
Tackling future issues - Hitting the cell in ovarian and endometrial cancers
PARP, mTOR, etc - Head and neck cancer
Viruses: Prevention and therapy
Innovations in radiation oncology (IMRT and image guided radiotherapy)
How to integrate EGFR inhibitors and beyond - Hematological malignancies
The role of high-dose therapy and allografting stemcell transplantation in the era of '-nibs' and '-mabs' - Communication skills in advanced cancer care
o The use of communication skills: Lessons derived from microanalytical studies
- Advances in soft tissue sarcoma, GIST and beyond
GIST - the role of adjuvant therapy and mutational analysis in treatment decision-making
Molecular biology and targeted therapy of sarcomas
Hyperthermia improves local control of STS - where next? - Emerging therapies for rare tumors
Neuroendocrine tumors, HCC, thyroid cancer, papillary RCC - Assessing, reporting and managing the safety of cancer drugs
Detecting safety signals
The role of pharmacogenetics in predicting and managing toxicity
Handling side effects of targeted therapies - Integration of targeted therapies with radiation
Where we are with radiation modifiers? - Unplanned analysis of molecular studies
Harmful or safe? - Cancer patients
o Should all receive prophylactically antithrombotic therapy?
o Dealing with difficult cases in daily clinical practice
- New developments in myeloma
Prognostic factors and the role of novel drugs
The status of transplantation - Glioma
From imaging to management - Recent progress in immunotherapy
Anti cancer vaccines
Combining immunotherapy with classical anti-cancer therapy - Advanced prostate cancer
The changing face of hormonal therapy
Diabetes and cardiovascular disease in prostate cancer survivors - Latest on oncology in developing countries
Cancer burden and the role of prevention
Balancing costs and benefits in cancer therapy and prevention - Drug development
How to recognize a promising drug: The role of clinical and biological endpoints
The role of regulatory bodies in the drug approval process
Late-breaking abstracts: oral sessions to present latest research studies with new research findings
Controversy sessions will create lively discussions on hot topics.
The 7th ESMO Patient Seminar where patients will have the chance to meet oncologists and hear about the conditions of cancer treatment in Europe, comparing conditions in Eastern and Western countries; discuss and confront doctors about the consequences of cancer therapy, learn the approaches to long-term survivorship and the future perspective of cancer treatments
Numerous Educational Sessions to present state-of-the-art oncology.
The fifth batch of ESMO Designated Centers of Integrated Oncology and Palliative Care will be announced as centers of excellence for patient care in Europe.
A session on ESMO Clinical Recommendations will update current ESMO Guidelines on clinical practice for various tumor types.
Oncology Highlights of the most important advances in cancer treatment in 2008.
And… Her Majesty Queen Silvia of Sweden accepted to be the Patron of the 33rd ESMO Congress and will give the welcome address during the Opening Ceremony
Meeting venue
The 33rd ESMO Congress will take place at the Stockholm International Fairs in Älvsjö, (Mässvägen 1, SE-12580 Stockholm-Älvsjö), located a short train journey from Stockholm Central Station.
The conference full program is available at http://www.esmo.org/activities/esmocongress/stockholm08/program_cng/
Accomodation
Congrex Sweden AB has been appointed by ESMO to manage hotel accommodation in relation to the 33rd ESMO Congress For hotel reservation, please visit: http://www.esmo.org/activities/esmocongress/stockholm08/accommodation_cng/
----------------------------
Article adapted by Medical News Today from original press release.
----------------------------
About the European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) is the leading European non-profit, professional organization for medical oncology promoting multidisciplinary cancer treatment around the world.
ESMO unites medical oncologists and other oncology specialists, healthcare professionals, caregivers, patients, policy-makers and all the key stakeholders in a global alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Through state-of-the-art education and training programs, ESMO plays an instrumental role in providing the oncology community with the most up-to-date scientific research and information available. ESMO is dedicated to educating and supporting oncologists, optimizing patient care, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative voice in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment. Through its flagship journal, Annals of Oncology, ESMO publishes articles on all aspects of clinical oncology.
To find out more about ESMO please visit http://www.esmo.org/
Source: Vanessa Pavinato
European Society for Medical Oncology
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |




